Roger Zhang is a Senior Associate at Samsara and joined the firm in 2020. He currently serves as a Director for two Samsara portfolio companies, Respira Therapeutics and Spyglass Pharma, as well as a board observer for multiple portfolio companies.
Prior to Samsara, Roger consulted in numerous roles across the drug development industry, including company formation with ARCH Venture Partners, biotech venture capital with Hillhouse Capital, business development with Maze Therapeutics and clinical development with Merck KGaA. While at Stanford, he founded the Mythos Biotechnology Fund, a student-led public biotech investment club. Prior to his PhD, Roger worked in early-stage R&D at Roche.
Roger received his B.Sc. in Pharmacology from the University of British Columbia and his Ph.D. in Molecular and Cellular Physiology from Stanford University, where he worked with Thomas Südhof on the functions of synaptic adhesion molecules.